The effect of alcohol and gemfibrozil co-administration in Wistar rats

In Vivo

Volumn 18, Issue 1, 2004, Pages 49-54

  Kolovou, Genovefa D ^a   Mikhailidis, Dimitri P ^b   Kafaltis, Nikolaos ^a   Adamopoulou, Evdokia N ^a   Yazitsoglou, Elefterios ^a   Hatzaki, Aggeliki ^a   Pilatis, Nectarios ^a   Margeli, Alexandra P ^c   Salpea, Klelia D ^a   Mykoniatis, Michael ^c   Cokkinos, Dennis V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Dyslipidaemia; Ethanol; Gemfibrozil; Liver; Transaminase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GEMFIBROZIL; MACROGOL; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ALCOHOL INTERACTION; HISTOPATHOLOGY; LIVER TOXICITY; MALE; NONHUMAN; PATHOGENESIS; RANDOMIZATION; RAT; RAT STRAIN; STANDARDIZATION; STATISTICAL SIGNIFICANCE; STOMACH TUBE; TOXICITY TESTING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 10744228676     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Todd PA and Ward A: Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 36(3): 314-39, 1988.
2. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P et al: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260(5): 641-51, 1988.
3. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP and Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85(1): 37-45, 1992.
4. Sausen PJ, Teets VJ, Voss KS, Miller RT and Cattley RC: Gemfibrozil-induced peroxisome proliferation and hepatomegaly in male F344 rats. Cancer Lett 97(2): 263-8, 1995.
5. Hofstra AH, King LM and Walker RM: Peroxisome proliferation and microsomal enzyme induction by the hypolipidemic CI-924 in rats and mice: relationship to tumorgenicity. Fundam Appl Toxicol 27: 277-286, 1995.
6. Goldberg IJ, Mosca L, Piano MR and Fisher EA: Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. AHA Science Advisory: Wine and your heart: a science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. Circulation 103: 472-475, 2001.
7. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S and Breteler MB: Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 153: 185-192, 1997.
8. Ruitenberg A, van Swieten JC, Witteman JC, Mehta KM, van Duijn CM, Hofman A and Breteler MMB: Alcohol consumption and risk of dementia: The Rotterdam Study. Lancet 359: 281-286, 2002.
9. Mukamal KJ, Jadhav PP, D'Agostino RB, Massaro JM, Mittleman MA, Lipinska I, Sutherland PA, Matheney T, Levy D, Wilson PWF, Ellison RC, Silbershatz H, Muller JE and Tofler GH: Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring Cohort. Circulation 104: 1367-1373, 2001.
10. Rimm EB, Klatsky A, Grobbee D and Stampfer MJ: Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine or spirits? BMJ 312: 731-736, 1996.
11. Feiman L and Lieber CS: Ethanol and lipid metabolism. Am J Clin Nutr 70: 791-792, 1999.
12. De Oliveira E Silva ER, Foster D, McGee Harper M, Seidman CE, Smith JD, Breslow JL and Brinton EA: Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation 102: 2347-2352, 2000.
13. Papadakis JA, Ganotakis ES and Mikhailidis DP: Beneficial effect of moderate alcohol consumption on vascular disease: myth or reality? J R Soc Health 120: 11-15, 2000.
14. Mikhailidis DP, Jeremy JY, Barradas MA, Green N and Dandona P: The effect of ethanol on vascular prostacyclin synthesis, platelet aggregation and platelet thromboxane release. Br Med J 287: 1495-1498, 1983.
15. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357(9260): 905-910, 2001.
16. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ and Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341(6): 410-8, 1999.
17. Kolovou GD, Mikhailidis DP, Daskalova DC, Kafaltis N, Adamopoulou EN, Malakos J, Bilianou HG, Theocharis SE, Pilatis ND, Mykoniatis MG and Cokkinos DV: The effect of co-administration of simvastatin and alcohol in rats. In Vivo 2003 (in press).
18. Hermansky SJ, Neptun DA, Loughran KA and Leung HW: Effects of polyethylene glycol 400 (PEG 400) following 13 weeks of gavage treatment in Fisher-344 rats. Fd Chem Toxic 33(2): 139-149, 1995.
19. Margeli A, Theocharis S, Skaltsas S, Skopelitou A, Kittas C, Mykoniatis M and Varonos D: Effect of cadmium pre-treatment on liver regeneration after partial hepatectomy in rats. Arch Toxicol 68: 85-90, 1994.
20. Margeli AP, Skaltsas SD, Spiliopoulou CA, Mykoniatis MG and Theocharis SE: Hepatic stimulator substance activity in the liver of thioacetamide-intoxicated rats. Liver 19: 519-525, 1999.
21. Theocharis SE, Margeli AP, Agapitos EV, Mykoniatis MG, Kittas CN and Davaris PS: Effect of hepatic stimulator substance administration on tissue regeneration due to thioacetamide-induced liver injury in rats. Scand J Gastroenterol 33: 656-663, 1998.
22. Nakagawa A, Shigeta A, Iwabuchi H, Horiguchi M, Nakamura K and Takahagi H: Simultaneous determination of gemfibrozil and its metabolites in plasma and urine by a fully automated high performance liquid chromatographic system. Biomed Chromatogr 5(2): 68-73, 1991.
23. Dix KJ, Coleman DP and Jeffcoat AR: Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley rats and Syrian golden hamsters. Drug Metab Dispos 27(1): 138-46, 1999.
24. Rubin E and Lieber CS: Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med 278:869-876, 1968.
25. Lieber CS: Metabolic derangement induced by alcohol. Ann Rev Med 18: 35-54, 1967.
26. Smit JWA, Wijnne HJA, Schobben F, Sitsen A, de Bruin TWA and Erkelens DW: Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin. Am J Cardiol 76: 89A-96A, 1995.
27. Makris TM, Davydov R, Denisov IG, Hoffman BM and Sligar SC: Mechanistic enzymology of oxygen activation by the cytochromes P450. Drug Metab Rev 34: 691-708, 2002.
28. Stickel F, Seitz HK, Hahn EC and Schuppan D: Alcoholic liver disease Z. Gastroenterol 41: 333-342, 2003.
29. Conney AH: Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19: 317-366, 1967.
30. Sharpe PC, McBride R and Archbold GP: Biochemical markers of alcohol abuse. QJM 89(2): 137-144, 1996.
31. Kraemer KL, Mayo-Smith MF and Calkins DR: Independent clinical correlates of severe alcohol withdrawal. Subst Abus 24(4): 197-209, 2003.
32. Pispirigos K, Simopoulos K, Kouskoukis K, Kounis N and Avramopoulos A: Evaluation of kidney and liver subacute toxicity induced by Bezalip-Pravastatin-Lopid antihyperlipidaemic compounds in rats. Biochem Mol Biol Int 47(3): 519-28, 1999.
33. Wirebaugh SR, Shapiro ML, McIntyre TH and Whitney EJ: A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin. Pharmacotherapy 12(6): 445-50, 1992.
34. Gunawardhana L, Mobley SA and Sipes IG: Modulation of 1,2-dichlorobenzene hepatotoxicity in the Fischer-344 rat by a scavenger of superoxide anions and an inhibitor of Kupffer cells. Toxicol Appl Pharmacol 119(2): 205-13, 1993.
35. Robinson SF and Quarfordt SH: The effect of ethanol on lipoprotein metabolism. Alcohol Clin Exp Res 5(1): 101-109, 1981.
36. Lieber CS and Savolainen M: Ethanol and lipids. Alcohol Clin Exp Res 8(4): 409-423, 1984.
37. Ginsberg H, Olefsky J, Farquhar JW and Reaven GM: Moderate ethanol ingestion and plasma triglyceride levels: a study in normal and hypertriglyceridemic persons. Ann Intern Med 80: 143-149, 1974.
38. MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW and Bokelman DL: Preclinical evaluation of lovastatin. Am J Cardiol 62: 16J-27J, 1988.
39. Bosma A, Seifert WF, van Thiel-de Ruiter GC, van Leeuwen RE, Blauw B, Roholl P, Knook DL and Brouwer A: Alcohol in combination with malnutrition causes increased liver fibrosis in rats. J Hepatol 21: 394-402, 1994.
40. Gerson RJ, Mac Donald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ and Bokelman DL: Animal safety and toxicology of simvastatin and related hydroxyl-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 87: 28S-38S, 1989.